High Purity Ss31 Oxytocin Acetate Dsip Pinealon Cortagen Foxo4-Drinad Ghk-Cu HMG Prostamax Pnc-27 PE-22-28 Dihexa Testagen Vilon Livagen Cardiogen
12 Inquiries
45234-02-4
99%
qingdao
JF
vials
2030-09-06
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332
-
Product Description
-
Seller Information
-
Inquiry History
-
DescriptionECHEMI Editorial ReferenceWhite powder
Solid
Lys-Glu is a dipeptide formed from L-lysine and L-glutamic acid residues. It has a role as a metabolite.Basic Info-
Product Name:
Lysylglutamic acid
Other Name:L-Glutamic acid,L-lysyl-;L-Glutamic acid,N-L-lysyl-;Glutamic acid,N-L-lysyl-;L-Lysyl-L-glutamic acid;Lysylglutamic acid;Vilon;Vilon (peptide);1072: PN: EP2071334 SEQID: 1140 claimed protein;1072: PN: WO2009077864 SEQID: 1140 claimed protein;72: PN: EP2161028 PAGE: 10 claimed protein;911649-46-2
CAS No.:45234-02-4
Molecular Formula:C11H21N3O5
InChIKeys:InChIKey=UGTZHPSKYRIGRJ-YUMQZZPRSA-N
Molecular Weight:275.3
Exact Mass:275.30
UNII:H34V7IM5ML
DSSTox ID:DTXSID50196442
HScode:2924199090
Categories:
Characteristics-
PSA:
156
XLogP3:0.66840
Density:1.29 g/cm3
Melting Point:195-197 °C
Boiling Point:596.4ºC at 760 mmHg
Flash Point:314.5ºC
Storage Conditions:-15°C
Research-
Class:
Angiotensin IV-derived oligopeptide / HGF-c-Met potentiator
Status:Research compound — Not FDA approved
Mechanism:A synthetic, orally active, blood-brain-barrier-permeable oligopeptide (Hexanoyl-Tyr-Ile-Ahx-NH₂) derived from angiotensin IV. Dihexa binds hepatocyte growth factor (HGF) with high affinity (Kd = 65 pM) and allosterically potentiates HGF activity at its receptor c-Met, promoting dendritic spinogenesis and synaptogenesis. In preclinical models it was reported to be seven orders of magnitude more potent than BDNF at promoting synapse formation. Note: the foundational 2014 paper (McCoy AT, et al. Neurobiol Learn Mem. 2014) was retracted in 2025.
EC50 (HGF Binding KD):65 pM
Activity note:Dihexa is an HGF potentiator, not a direct receptor agonist. It does not activate c-Met alone but markedly augments HGF-induced c-Met activation at low nanomolar HGF concentrations. Functional synaptogenic activity was reported at 10⁻¹°–10⁻⁻ M (original data now subject to retraction).
Source:Original report: McCoy AT, et al. Neurobiol Learn Mem. 2014;115:112-120 (retracted 2025). Benoist CC, et al. J Pharmacol Exp Ther. 2014;351(3):628-637.
Clinical Development:
References-
PubChem:UNII:Literature:
Benoist CC, et al. J Pharmacol Exp Ther. 2014 — HGF/c-Met mechanism; McCoy AT, et al. Neurobiol Learn Mem. 2014 — Synaptogenesis data (Retracted 2025); Athira Pharma: Fosgonimeton (prodrug) pipeline status
Disclaimer:Dihexa is NOT FDA-approved or EMA-approved as a medicine. It is a research compound only. The foundational 2014 paper describing its synaptogenic potency was retracted in 2025. Its phosphate prodrug fosgonimeton failed a Phase 2/3 Alzheimer’s trial (LIFT-AD, 2024). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Weight Loss Peptide,Reta,Tirz,Sema,5 Amino 1mq,Cosmetic raw material,API,SLU-PP-332
-
Location:
Unit D01,3/F., Wong King Industrial Building,No.2 Tai Yau Street, Kowloon
-
Payment Terms:
TT against copy of documents,D/P,L/C,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
7
-
Total Annual Revenue:
$50 million-$100 million
-
Total Employees:
51-100
-
Year of Establishment:
2012
-
-
Inquiry History12 Inquiries
Country Product Purchase Quantity Date Posted
United Arab Emirates
Vesugen Peptide 98% Powder 45234-02-4 Senwayer
1 G Nov 14, 2023
Philippines
VILON
300 G Aug 26, 2026
United States
Cartalax
20 MG Aug 6, 2026
United States
Vilon
1 KG Jul 8, 2026
Brazil
Cartalax
5 MT Apr 17, 2026
Poland
Peptides
10 MT Aug 24, 2026
United States
Cartalax
20 MG Aug 17, 2026
Australia
Cartalax
200 MG Jul 3, 2026
United States
Cartalyx
1 PCS Mar 12, 2026
United States
Cartalax
1 G Jul 25, 2026
Netherlands
Cartalax
1 G Apr 26, 2026
United States
Vesugen 10mg
20 PCS Mar 3, 2026 Post an enquiry for this product